Key result
Dose-adjusted R-EPOCH chemotherapy resulted in symptomatic resolution of ventricular tachycardia and a complete metabolic response of the right ventricular mass after two cycles.
Why the study?
Primary cardiac involvement of diffuse large B-cell lymphoma is rare and frequently presents with subtle, atypical symptoms that complicate diagnosis and management.
Case Report (n=1)
No
Dose-adjusted R-EPOCH chemotherapy can be an effective treatment for primary cardiac diffuse large B-cell lymphoma, achieving rapid complete metabolic response.
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma. However, primary cardiac involvement is rare, often presenting with subtle and atypical symptoms that complicate diagnosis and management. We present the case of a 60-year-old man who presented with intermittent palpitations of unclear origin, later identified as ventricular tachycardia. Imaging showed a right ventricular cardiac mass, and biopsy confirmed a diagnosis of DLBCL. He was treated with the chemotherapy regimen rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R-EPOCH), resulting in symptomatic resolution of palpitations and a reduction in the size of the cardiac mass. Early detection is crucial to improving survival in primary cardiac lymphomas and highlights the importance of an interdisciplinary approach in managing this rare cardiac malignancy.
No takes yet. Share an insight, caveat, or question.
Roufeh et al. (2025) conducted a case report in Primary Cardiac Diffuse Large B-Cell Lymphoma (n=1). R-EPOCH (rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) was evaluated on Tumor response. Dose-adjusted R-EPOCH chemotherapy resulted in symptomatic resolution of ventricular tachycardia and a complete metabolic response of the right ventricular mass after two cycles.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: